# US 2016/0250152 A1 · Nanogel-Mediated Drug Delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250152 A1
- Document ID: US20160250152A1
- Status: Published application
- Kind: A1
- Application number: 15/011,467
- Filed: 2016-01-29
- Published: 2016-09-01
- Earliest claimed: 2012-10-05
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Vinod Labhasetwar; Yogen Saunthararajah; Sivakumar Vijayaraghavalu
- Web page: https://patentgrep.com/patent/US20160250152A1

## CPC

- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.

## Claims

### Claim 1

A method of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel.

### Claim 2 (depends on 1)

The method of claim 1 wherein the tumor cells are further contacted with one or more chemotherapeutic drugs.

### Claim 3 (depends on 2)

The method of claim 2 wherein the one or more chemotherapeutic drugs are encapsulated in a nanogel.

### Claim 4 (depends on 3)

The method of claim 3 wherein the one or more chemotherapeutic drugs are encapsulated in the nanogel that encapsulates the one or more epigenetic drugs or the one or more chemotherapeutic drugs are encapsulated in a separate nanogel.

### Claim 5 (depends on 2)

The method of claim 2 wherein the tumor cells are first contacted with the one or more epigenetic drugs and then contacted with the one or more chemotherapeutic drugs.

### Claim 6 (depends on 1)

The method of claim 1 wherein the tumor cells are drug resistant tumor cells, sensitive tumor cells, metastatic tumor cells or a combination thereof.

### Claim 7 (depends on 6)

The method of claim 6 wherein the cells are contacted with an effective dose of the one or more chemotherapeutic drugs that is lower than the effective dose of the one or more chemotherapeutic drug when the one or more chemotherapeutic drugs are administered without the composition comprising the epigenetic agent encapsulated in the nanogel.

### Claim 8

A method of treating a tumor, metastasis of a tumor or a combination thereof, said tumor comprising tumor cells, in an individual in need thereof comprising administering a therapeutically effective amount of a composition comprising one or more epigenetic drugs that alter one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel, to the individual.

### Claim 9 (depends on 8)

The method of claim 8 wherein the tumor cells are further contacted with one or more chemotherapeutic drugs.

### Claim 10 (depends on 9)

The method of claim 9 wherein the one or more chemotherapeutic drugs are encapsulated in a nanogel.

### Claim 11 (depends on 10)

The method of claim 10 wherein the one or more chemotherapeutic drugs are encapsulated in the nanogel that encapsulates the one or more epigenetic drugs or the one or more chemotherapeutic drugs are encapsulated in a separate nanogel.

### Claim 12 (depends on 8)

The method of claim 8 wherein the tumor cells are first contacted with the one or more epigenetic drugs and then contacted with the one or more chemotherapeutic drugs.

### Claim 13 (depends on 8)

The method of claim 8 wherein the tumor cells are drug resistant tumor cells, sensitive tumor cells, metastatic tumor cells or a combination thereof.

### Claim 14 (depends on 8)

The method of claim 8 wherein the cells are contacted with an effective dose of the one or more chemotherapeutic drugs that is lower than the effective dose of the one or more chemotherapeutic drug when the one or more chemotherapeutic drugs are administered without the composition comprising the epigenetic agent encapsulated in the nanogel.

### Claim 15

A composition comprising one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.

### Claim 16 (depends on 15)

The composition of claim 15 further comprising one or more chemotherapeutic drugs encapsulated in a nanogel.

### Claim 17 (depends on 16)

The composition of claim 16 wherein the one or more epigenetic drugs and the one or more chemotherapeutic drugs are encapsulated in the same nanogel.

### Claim 18 (depends on 17)

The composition of claim 17 wherein the one or more chemotherapeutic drug is loaded in the nanogel's core and the one or more epigenetic drugs are loaded in the nanogel's corona.

### Claim 19 (depends on 15)

A pharmaceutical composition comprising the composition of claim 15.

### Claim 20 (depends on 17)

A method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor, comprising administering a therapeutically effective amount of a composition comprising the composition of claim 17 to the individual.

### Claim 21 (depends on 1)

The method of claim 1 wherein the nanogel is about 200 nm or smaller in diameter.

### Claim 22 (depends on 21)

The method of claim 21 wherein the nanogel is about 50 nm or smaller in diameter.

### Claim 23 (depends on 1)

The method of claim 1 wherein the nanogel has sustained drug release properties.

### Claim 24 (depends on 8)

The method of claim 8 wherein the nanogel is about 200 nm or smaller in diameter.

### Claim 25 (depends on 24)

The method of claim 24 wherein the nanogel is about 50 nm or smaller in diameter.

### Claim 26 (depends on 8)

The method of claim 8 wherein the nanogel has sustained drug release properties.

### Claim 27 (depends on 15)

The composition of claim 15 wherein the nanogel is about 200 nm or smaller in diameter.

### Claim 28 (depends on 27)

The composition of claim 27 wherein the nanogel is about 50 nm or smaller in diameter.

### Claim 29 (depends on 15)

The composition of claim 15 wherein the nanogel has sustained drug release properties.

### Claim 30 (depends on 1)

The method of claim 1 wherein the one or more epigenetic drugs encapsulated in a nanogel are not metabolized by cytidine deaminase prior to their release from the nanogel.

### Claim 31 (depends on 8)

The method of claim 8 wherein the one or more epigenetic drugs encapsulated in a nanogel are not metabolized by cytidine deaminase prior to their release from the nanogel.

### Claim 32 (depends on 15)

The composition of claim 15 wherein the one or more epigenetic drugs encapsulated in a nanogel are not metabolized by cytidine deaminase prior to their release from the nanogel after administration into an individual.

### Claim 33 (depends on 1)

The method of claim 1 wherein the one or more epigenetic drugs encapsulated in the nanogel alters the formation of exosomes secreted by the tumor cells.

### Claim 34 (depends on 8)

The method of claim 8 wherein the one or more epigenetic drugs encapsulated in the nanogel alters the formation of exosomes secreted by the tumor cells.

### Claim 35 (depends on 15)

The composition of claim 15 wherein the one or more epigenetic drugs encapsulated in the nanogel alters the formation of exosomes secreted by the tumor cells.
